AmpliPhi Biosciences Announces $18 Million Private Placement

Link to press release here. RICHMOND, VA, US, COLWORTH, UK and SYDNEY, AUSTRALIA, December, 16 2013 – AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a […]

Avita Medical Update to Shareholders

ASX announcement link here. Avita CFO Mr Tim Rooney appointed interim CEO following resignation of Managing Director and CEO William Dolphin. Ian MacPherson elected as interim board Chairman following resignation of Dalton Gooding as Chairman. Internal progress made to review company remuneration report.

Scottish Medicines Consortium Accepts Bronchitol For Use In Cystic Fibrosis Patients

Link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced that the Scottish Medicines Consortium (SMC) has accepted Bronchitol® (mannitol dry powder for inhalation) for use by the National Health Service in Scotland.  Bronchitol is licensed for the treatment of adult cystic fibrosis (CF) patients aged 18 years and above as an add-on therapy to best standard of […]

Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere

Announcement link here. ATLANTA, Dec. 5, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the “Company”) today announced that it has commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI). The trial, referred to as “IGLOO”, compares the safety […]

Nexvet unveils clinical data supporting its novel pain treatment for dogs

04 December, 2013. Link here. Leading veterinary biologic drug developer Nexvet Biopharma (Nexvet) today announced promising clinical data in support of its novel compound NV-01 for treating acute and chronic pain in dogs.

Bioxyne Ltd CEO Steps Down

ASX announcement here. Bioxyne Limited (ASX code: BXN or the Company) advises that subsequent to the execution of a non-binding Heads of Agreement (HOA) to sell its HI-164 oral Vaccine project together with all of its Intellectual properties (IP) to Mariposa Health Limited (MHL), Dr. Phillip Comans has stepped down as Chief executive Officer of the […]

Bioxyne Ltd – Sale of HI-164OV Hunter Immunology Pty Ltd

Please find the ASX announcement here. Bioxyne divests its COPD related HI-164OV research program for up to $1.56 million.